Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0051098 | Colorectum | AD | regulation of binding | 126/3918 | 363/18723 | 6.01e-10 | 4.88e-08 | 126 |
GO:0022411 | Colorectum | AD | cellular component disassembly | 147/3918 | 443/18723 | 8.53e-10 | 6.76e-08 | 147 |
GO:0022604 | Colorectum | AD | regulation of cell morphogenesis | 109/3918 | 309/18723 | 3.08e-09 | 2.07e-07 | 109 |
GO:0007163 | Colorectum | AD | establishment or maintenance of cell polarity | 77/3918 | 218/18723 | 5.72e-07 | 2.08e-05 | 77 |
GO:1903008 | Colorectum | AD | organelle disassembly | 46/3918 | 114/18723 | 1.81e-06 | 5.48e-05 | 46 |
GO:0000422 | Colorectum | AD | autophagy of mitochondrion | 35/3918 | 81/18723 | 4.94e-06 | 1.29e-04 | 35 |
GO:0061726 | Colorectum | AD | mitochondrion disassembly | 35/3918 | 81/18723 | 4.94e-06 | 1.29e-04 | 35 |
GO:0043393 | Colorectum | AD | regulation of protein binding | 68/3918 | 196/18723 | 5.17e-06 | 1.34e-04 | 68 |
GO:0008360 | Colorectum | AD | regulation of cell shape | 56/3918 | 154/18723 | 7.01e-06 | 1.73e-04 | 56 |
GO:0016055 | Colorectum | AD | Wnt signaling pathway | 130/3918 | 444/18723 | 1.60e-05 | 3.37e-04 | 130 |
GO:0198738 | Colorectum | AD | cell-cell signaling by wnt | 130/3918 | 446/18723 | 2.02e-05 | 4.10e-04 | 130 |
GO:0046777 | Colorectum | AD | protein autophosphorylation | 74/3918 | 227/18723 | 2.48e-05 | 4.76e-04 | 74 |
GO:0010975 | Colorectum | AD | regulation of neuron projection development | 129/3918 | 445/18723 | 2.88e-05 | 5.37e-04 | 129 |
GO:0007409 | Colorectum | AD | axonogenesis | 122/3918 | 418/18723 | 3.36e-05 | 6.15e-04 | 122 |
GO:0030010 | Colorectum | AD | establishment of cell polarity | 50/3918 | 143/18723 | 6.90e-05 | 1.11e-03 | 50 |
GO:0031346 | Colorectum | AD | positive regulation of cell projection organization | 104/3918 | 353/18723 | 8.26e-05 | 1.30e-03 | 104 |
GO:0061564 | Colorectum | AD | axon development | 132/3918 | 467/18723 | 8.40e-05 | 1.31e-03 | 132 |
GO:0033674 | Colorectum | AD | positive regulation of kinase activity | 131/3918 | 467/18723 | 1.28e-04 | 1.85e-03 | 131 |
GO:0045197 | Colorectum | AD | establishment or maintenance of epithelial cell apical/basal polarity | 20/3918 | 44/18723 | 2.26e-04 | 2.94e-03 | 20 |
GO:0035088 | Colorectum | AD | establishment or maintenance of apical/basal cell polarity | 21/3918 | 49/18723 | 4.31e-04 | 4.82e-03 | 21 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MARK2 | SNV | Missense_Mutation | | c.2144N>A | p.Arg715His | p.R715H | Q7KZI7 | protein_coding | deleterious(0) | probably_damaging(0.915) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
MARK2 | SNV | Missense_Mutation | | c.2050G>C | p.Glu684Gln | p.E684Q | Q7KZI7 | protein_coding | tolerated(0.08) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MARK2 | SNV | Missense_Mutation | novel | c.1312G>C | p.Glu438Gln | p.E438Q | Q7KZI7 | protein_coding | tolerated(0.23) | benign(0.018) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
MARK2 | SNV | Missense_Mutation | | c.1075C>A | p.Leu359Met | p.L359M | Q7KZI7 | protein_coding | deleterious(0.01) | possibly_damaging(0.654) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
MARK2 | SNV | Missense_Mutation | | c.316N>C | p.Val106Leu | p.V106L | Q7KZI7 | protein_coding | tolerated(0.79) | benign(0) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MARK2 | SNV | Missense_Mutation | rs368859674 | c.1307N>A | p.Arg436Gln | p.R436Q | Q7KZI7 | protein_coding | tolerated(0.79) | benign(0.007) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
MARK2 | SNV | Missense_Mutation | rs199684279 | c.905N>A | p.Arg302Gln | p.R302Q | Q7KZI7 | protein_coding | deleterious(0) | possibly_damaging(0.606) | TCGA-XX-A899-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
MARK2 | insertion | Nonsense_Mutation | novel | c.908_909insCCCCAGAACTCTTCCAGGGCAAAAAATATGATGGACCC | p.Trp303CysfsTer11 | p.W303Cfs*11 | Q7KZI7 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
MARK2 | insertion | Frame_Shift_Ins | novel | c.876_877insTCCTCTC | p.Gly293SerfsTer21 | p.G293Sfs*21 | Q7KZI7 | protein_coding | | | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
MARK2 | insertion | Nonsense_Mutation | novel | c.879_880insCTCTGGTCTTAGCCCTGACCTCCTGCCTTTGCC | p.Gly293_Thr294insLeuTrpSerTerProTerProProAlaPheAla | p.G293_T294insLWS*P*PPAFA | Q7KZI7 | protein_coding | | | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | TOZASERTIB | TOZASERTIB | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | LINIFANIB | LINIFANIB | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | DOVITINIB | DOVITINIB | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | GSK-269962A | GSK-269962A | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | TYROSINE KINASE INHIBITORS | | 15811957 |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | GNF-PF-2301 | CHEMBL578061 | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | KENPAULLONE | KENPAULLONE | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | CENISERTIB | CENISERTIB | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | ALSTERPAULLONE | ALSTERPAULLONE | |
2011 | MARK2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | | AZD-1080 | AZD-1080 | |